Q2 Earnings Estimate for Zymeworks Issued By HC Wainwright

Zymeworks Inc. (NYSE:ZYME - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2025 earnings estimates for Zymeworks in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.45) for the quarter, up from their prior estimate of ($0.47). HC Wainwright currently has a "Neutral" rating and a $13.00 price target on the stock. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.04) EPS.

Several other equities analysts have also weighed in on the stock. Lifesci Capital began coverage on shares of Zymeworks in a report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price on the stock. Citigroup increased their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, March 7th. TD Securities initiated coverage on shares of Zymeworks in a research report on Tuesday, May 20th. They issued a "buy" rating on the stock. Finally, TD Cowen started coverage on shares of Zymeworks in a research note on Tuesday, May 20th. They set a "buy" rating for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Zymeworks Trading Down 1.2%

ZYME traded down $0.14 during trading on Thursday, hitting $11.40. The company's stock had a trading volume of 71,204 shares, compared to its average volume of 598,528. The business's fifty day simple moving average is $11.73 and its 200 day simple moving average is $13.24. Zymeworks has a twelve month low of $8.21 and a twelve month high of $17.70. The firm has a market capitalization of $793.32 million, a price-to-earnings ratio of -7.62 and a beta of 1.24.

Zymeworks (NYSE:ZYME - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The firm had revenue of $27.11 million during the quarter, compared to analyst estimates of $20.65 million. During the same quarter in the previous year, the business earned ($0.42) earnings per share. Zymeworks's quarterly revenue was up 170.3% on a year-over-year basis.

Insider Buying and Selling at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 320,690 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average cost of $11.49 per share, with a total value of $3,684,728.10. Following the completion of the acquisition, the director now directly owns 16,040,851 shares of the company's stock, valued at $184,309,377.99. This represents a 2.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased a total of 1,405,768 shares of company stock worth $16,773,032 over the last 90 days. Insiders own 1.92% of the company's stock.

Hedge Funds Weigh In On Zymeworks

Institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC raised its stake in Zymeworks by 781.5% in the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock valued at $25,000 after acquiring an additional 1,524 shares during the period. CWM LLC raised its position in shares of Zymeworks by 1,091.2% during the first quarter. CWM LLC now owns 2,299 shares of the company's stock worth $27,000 after acquiring an additional 2,106 shares during the last quarter. AlphaQuest LLC raised its position in shares of Zymeworks by 480.2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock worth $41,000 after acquiring an additional 2,324 shares during the last quarter. GAMMA Investing LLC increased its holdings in Zymeworks by 1,113.3% in the first quarter. GAMMA Investing LLC now owns 6,467 shares of the company's stock worth $77,000 after purchasing an additional 5,934 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in shares of Zymeworks during the fourth quarter valued at approximately $108,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.